Immunotherapy Advances in CRC

CME

Integrating Emerging Insights Into Clinical Practice: Expert Roundtable on Immunotherapy Advances in Colorectal Cancer From the Gastrointestinal Cancers Symposium

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 10, 2025

Expiration: September 09, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Currently, how confident are you in your ability to integrate ICIs into the treatment of colorectal cancer throughout the disease continuum?

2.

Which of the following patients with locally advanced rectal cancer could be considered for neoadjuvant immune checkpoint inhibitor monotherapy?

3.

After 2 cycles of nivolumab + ipilimumab, a patient with mCRC develops fatigue and fever. Testing reveals grade 3 transaminitis, with a diagnosis of immune hepatitis. In your current practice, how would you manage this patient?